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INTRODUCTION 
 
Death from cancer represents around one eighth of all deaths in the world. In the past 30 years, the 
yearly detected new cases of cancer patients have been doubled. In 2008 approximately 12.7 million new 
patients were diagnosed with cancer, and an estimated 7.6 million people died of cancer in the world. In 
the WHO European Region 3.4 million people were diagnosed with and 1.8 million people died of 
cancer. This represents more than 23% of the people who died from cancer all over the world. However, 
the population of this region represents less than 15% of the world's population. The higher ratio is the 
consequence of the aging population with a bulge-number of middle age and decreasing number of births 
in the younger age categories. 
In Hungary, the number of cancer patients has been dramatically increased in the 20th century due to 
the aging and civilization harms, but it has been more or less stabilized in the last 20 years at around 
70.000. At present, there are about 300.000 cancer patients and 32.460 people died of malignant 
neoplastic diseases in Hungary in 2010. Cancer is the second most frequent cause of death following 
cardiovascular diseases with 47.743 deaths in 2010 in Hungary according to the KSH (Hungarian Central 
Statistical Office) data. 
Due to the aging of the population predicted for the next decades, cancer incidence will 
dramatically raise. Therefore, scientific discovery into new approaches to cancer treatment and prediction 
is even more urgent. 
A complete understanding of the mechanisms of the cancer development is very unlikely to come 
about in the foreseeable future making impossible reliance on a single approach to prevent cancer and 
deaths from the disease. Pharmacological research is of paramount importance from basic research to 
clinical phase studies. The development of new anticancer drugs can not only improve the efficacy of 
treatment, but it can reduce the side effects with the understanding of the mechanism of action. In cancer 
research, genetic aspects have become even more important for revealing the molecular basis of the 
disease that can have a predictive value in cancer development and can contribute to forecast the efficacy 
of treatment. 
 
Cancer cell resistance to drugs is of paramount importance when evaluating response to 
chemotherapy; therefore, its relevance is unambiguous in clinical practice. Treatment failure can be due 
to pharmacokinetic mechanisms, also called pharmacokinetic resistance; the consequence is decreased 
drug exposure of cancer cells. Multidrug resistance (MDR) is the main reason for the reduced effect of 
chemotherapy in many cancer types. Experimentally, tumor cells in vitro exposed to one cytotoxic agent 
develop cross-resistance to a range of structurally and functionally unrelated compounds. A number of 
different mechanisms can mediate the development of drug or multidrug resistance in cancer. Here we 
focused our research on membrane transporters and single nucleotide polymorphisms (SNPs). 
 
In ovarian cancer, up to two-thirds of tumor specimens have been found to overexpress ABCB1 
(ATP-binding transporter B1) membrane transporter and this overexpression has been shown to correlate 
with poor overall survival. However, in case of the A2780cis cisplatin-resistant ovarian cancer cell line, 
ABCB1 overexpression does not seem to be important in cisplatin resistance. There are other gene 
families that are supposed to be responsible for cisplatin resistance: copper transporters and P-type 
transporters. Their members are localized in the plasma membrane such as CTR1 (copper transporter 1), 
or localized in the intracellular membranes such as CTR2 (copper transporter 2) or ATP7A and ATP7B 
(P-type copper transporters α and β). 
ABC transporters couple the hydrolysis of ATP to move drugs and xenobiotics unidirectional out 
of the cells, thereby promoting drug resistance. These transporters are membrane proteins consisting of 
both transmembrane domains and distinctive nucleotide binding domains. The nucleotide binding 
domains generate energy from ATP hydrolysis to actively transport a variety of compounds across the 
plasma membrane. Nowadays, twenty ABC transporters have been associated with multidrug resistance. 
In our investigation we focused on a human ABCB1-transfected mouse lymphoma cell line. Normally, 
ABCB1 is expressed in the apical membrane of many secretory cell types, such as kidney, liver, intestine, 
adrenal gland, and the blood-brain barrier where the normal function involves the excretion of drugs and 
 2 
their metabolites. The expression of ABCB1 in this cell line is constitutively high enough to be a good 
model cell line to examine the ABCB1-linked drug resistance. Due to the nature of ABCB1 as an efflux 
pump for cell protection against a variety of substances, its substrates vary greatly in size, structure and 
function, ranging from small molecules, such as organic cations, carbohydrates, amino acids, and some 
antibiotics to macromolecules, such as polysaccharides and proteins. 
Current evidence suggests that one component of cisplatin uptake is mediated by the CTR1 and 
CTR2. CTR1 has been described as the major copper influx transporter that controls the uptake of 
platinum-containing drugs, such as cisplatin, carboplatin and oxaliplatin via coupled-transport. According 
to recent studies, it has been shown that mammalian cells express a second structurally related transporter, 
CTR2, whose function is less well-defined. CTR2 is predominantly localized in endosomes and 
lysosomes in mammalian cells; however, when expressed at the cell surface, CTR2 is capable of 
mediating copper uptake as well. A number of studies have demonstrated that besides CTRs, ATP7A and 
B modulate the export of cisplatin. These Cu-ATPases represent a large superfamily of P-type membrane 
transporters which use the energy of ATP hydrolysis to transport copper and cisplatin across cell 
membranes. 
Several compounds have been found as promising MDR modifiers e.g. flavonoids and 
phenothiazines such as chlorpromazines, stilbenes, di- and triterpenes and carotenoids at the Department 
of Medical Microbiology and Immunobiology in the last 30 years. Furthermore, specifically modified 
compounds such as metal coordination complexes of tricyclic compounds have also been investigated, 
since it has been assumed that metals induce some changes in binding features to ABCB1. At present, a 
number of metal-based compounds, such as ruthenium(II) organometallic arene complexes or tetrahedral 
Au(I) phosphine complexes, are known to have promising antiproliferative effects in a wide range of 
tumors.  
Therefore, we tried to combine the advantages of platinum- and copper-based coordination 
complexes and resistance modifier steroid compounds in a wish to overcome drug resistance in a 
cisplatin-resistant human ovarian cancer cell line (A2780cis) directly through copper transporters and in a 
human ABCB1 gene-expressing mouse T-lymphoma cell line (MDR). Other compounds of synthetic 
(hydantoin derivatives) and natural origin (steroidal alkaloids, saponins and phenolic components) were 
also investigated to reverse drug resistance. 
 
Cancer is a consequence of genetic changes in certain tumor suppressor genes and proto-oncogenes. 
Resistance can also be caused by SNPs of membrane transporters which can be hereditary in many cancer 
types, such as breast and ovarian cancer. SNPs can also alter the ability of a protein to bind its substrates 
or inhibitors and change the subcellular localization of proteins. These small genetic changes may be 
responsible for medicinal drug deposition and disease susceptibility, which have already been verified in 
certain diseases, such as age-related cortical cataract, diabetes mellitus and cancer. Therefore, another 
objective of our research was to define the relationship between certain SNPs and cancer 
complementing our knowledge about sequence – protein function relationships of the examined genes and 
encoded proteins. 
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AIMS 
The main aim of our recent study was to evaluate the effects of synthetic and natural compounds on drug 
resistance in a hormone-independent cisplatin-resistant human ovarian cancer cell line (A2780cis) and in 
a human ABCB1 gene-transfected doxorubicin-resistant mouse T-lymphoma cell line (MDR). 
Furthermore, distributions of certain single nucleotide polymorphisms in cancer-related genes were also 
investigated. 
The goals of the study are as follows: 
1. Characterization of the examined cell lines (A2780/A2780cis and PAR/MDR) by 
immunocytochemistry by using specific monoclonal antibodies to determine the expression of 
certain proteins, such as ABCB1, MRP1, estrogen and progesterone receptors. 
2. Determination of the antiproliferative effects of compounds (steroids and platinum/copper 
complexes, hydantoin derivatives, steroidal alkaloids of Veratrum lobelianum, V. nigrum and 
Peganum nigelastrum, saponins and phenolic components of Tribulus terrestris and Smilax 
excelsa) in A2780cis and/or MDR cells. 
3. Evaluation of the MDR reversal effects of compounds (steroids and platinum/copper complexes, 
hydantoin derivatives, steroidal alkaloids of Veratrum lobelianum, V. nigrum and Pergamum 
nigelastrum, saponins and phenolic components of Tribulus terrestris and Smilax excelsa) on 
A2780cis and/or MDR cell lines.  
4. Combination of selected resistance modifiers and some anticancer agents doxorubicin and 
cisplatin to determine their mode of interaction by checkerboard microplate method in 
A2780cis and/or MDR cells. 
5. Apoptosis induction in A2780cis and MDR cells by selected substituted steroids, and their 
platinum- and copper-complexes. 
6. Evaluation of allele distributions of single nucleotide polymorphisms of cancer-related genes 
by PCR-RFLP. 
 
MATERIALS AND METHODS 
Cell cultures 
PAR/MDR. Parental (PAR) mouse T-cell lymphoma cells (ECACC cat. no. 87111908) were transfected 
with pHa ABCB1/A retrovirus. The human ABCB1-expressing cell line L5178Y was selected by 
culturing the infected cells with 60 ng/ml colchicine to maintain the expression of the MDR phenotype. 
The PAR and the human ABCB1 gene-transfected subline (MDR) were cultured at 37○C in McCoy's 5A 
media (Sigma-Aldrich) supplemented with 10% heat-inactivated horse serum (H1270, Sigma-Aldrich), L-
glutamine 200 mM (Invitrogen) and penicillin-streptomycin mixture (Sigma-Aldrich) in 100U/l and 100 
mg/l concentration, respectively. The media for culturing the MDR cell line was complemented with 
colchicine (60 ng/ml, Sigma-Aldrich). These mouse lymphoma cell lines were maintained in a 5% CO2 
incubator at 37○C. 
A2780/A2780cis. A2780cis cell line (ECACC cat. no. 93112517) was developed by chronic exposure of 
the parental cisplatin-sensitive A2780 human ovarian cancer cell line to increasing concentrations of 
cisplatin. These cell lines were cultured in RPMI 1640 media (Sigma-Aldrich Co.) supplemented with 
10% heat-inactivated fetal bovine serum (10106-169, GIBCO, Invitrogen), L-glutamine (200mM) and 
penicillin-streptomycin mixture in 100U/l and 100 mg/l concentration, respectively. In order to retain 
resistance of A2780cis cells, cisplatin (Teva Pharma) was added to the media every 2-3 passages at 1 µM 
final concentration. The ovarian cancer cell lines were maintained in a 5% CO2 incubator at 37○C. 
Compounds 
Semisubstituted steroids and their derivatives in complex with platinum and copper salt (I). We 
examined thirty-five modified steroid (1-35) derivatives provided by Prof. Irén Vincze (Department of 
Organic Chemistry, University of Szeged) and Dr. Csaba Somlai (Department of Medical Chemistry, 
University of Szeged). Then, we evaluated three selected compounds (4, 5, 25) and their copper (4C, 5C, 
25C) and platinum coordination complexes (4P, 5P, 25P), these compounds were provided by Dr. Imre 
Labádi (Department of Inorganic and Analytical Chemistry, University of Szeged). 
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Hydantoin derivatives (II). We investigated thirty hydantoin derivatives (SZ-2, SZ-7, LL-9, BS-1, JH-63, 
MN-3, TD-7k, GG-5k, P3, P7, P10, P11, RW-15b, AD-26, RW-13, AD-29, KF-2, PDPH-3, Mor-1, KK-
XV, Thioam-1, JHF-1, JHC-2, JHP-1, Fur-2, GL-1, GL-7, GL-14, GL-16, GL-18) which were provided 
by Dr. Jadwiga Handzlik and Prof. Katarzyna Kieć-Kononowich (Department of Technology and 
Biotechnology of Drugs, Jagiellonian University, Cracow, Poland).  
Steroidal alkaloids of Veratrum and Peganum species (III, IV). We examined nine alkaloids (A1-9): 
neogermitrine (A1), verabenzoamine (A2), veratroilzigadenine (A3), 15-O-(2-methylbutyroyl)germine 
(A4), veralosinine (A5), veranigrine (A6), deoxypeganine (A7), harmine (A8) and peganine (A9) isolated 
prevoiusly from the roots and rhizomes of three Mongolian species (Veratrum lobelianum, V. nigrum, 
Melanthiaceae; Peganum nigelastrum, Nitrariaceae) by Veselin Christov et al. and Antoaneta Ivanova et 
al. (Institute of Organic Chemistry with Centre of Phytochemistry, Bulgarian Academy of Sciences, 
Sofia, Bulgaria). 
Saponins and phenolic components of Tribulus terrestris and Smilax excelsa (V). We evaluated six 
pure steroidal saponins (S-4, S8, S9), a mixture of three saponin isomers (S5-7), and two phenolic 
components (S10, S11) isolated from the saponin fractions of Tribulus terrestris (Zygophyllaceae) and 
Smilax excelsa (Smilacaceae) by Antoaneta Ivanova et al. (Institute of Organic Chemistry with Centre of 
Phytochemistry, Bulgarian Academy of Sciences, Sofia, Bulgaria). 
Methods 
Immunocytochemistry. The immunocytochemical investigations were carried out at the National Institute 
of Oncology (Budapest, Hungary). Cancer cells were cultured and resuspended in serum-free media to a 
density of 1×106 cells/ml. 100 µl cell suspension was centrifuged at 1.000 rpm for 5 min by a Shandon 
Cytospin 3 centrifuge (Thermo Fisher Scientific), then Giemsa-stain was applied for one of each sample. 
The slides were fixed in acetone at -20○C for 10 min and were washed for 5 min in TBS. The 
investigations were performed in a wet chamber. 
The following monoclonal antibodies (MABs) were applied to detect the cell membrane proteins: 
NCL-JSB1 (for ABCB1; NovocastraTM, Leica Biosystems), NCL-PGLYm (for ABCB1; NovocastraTM), 
NCL-MRP1 (for MRP1; NovocastraTM), NCL PGR 312 (for progesterone receptor; NovocastraTM), SP1 
RM 9101-S (for estrogen receptor; Neomarkers, Thermo Fisher Scientific). MCF7 breast cancer cell line 
was applied as a control. The smears were washed with PBS. Endogenous peroxidases were quenched in 
0.03% H2O2 + NaN3 for 10 min and washed with PBS. The samples were incubated for 1 h at room 
temperature with primary MABs, 100 µl of the MABs (anti-ABCB1, anti-MRP1 10x; anti-estrogen 200x; 
anti-progesterone 180x diluted in PBS) and the positive control cytokeratinase (25x diluted in PBS) were 
added. Then, DAKO Cytomation EnVision+ System-HRP (AEC) kit (DAKO North America) was 
applied according to manufacturer’s instructions to detect the red end-product of the cleavage by 
horseradish peroxidase under microscope. Finally, haematoxylin-eosin staining was carried out and cover 
slips placed over the slides containing the samples (wet mounts) with Dako Cytomation Faramount 
Adequous Mounting. Then, photographed with a Nikon Microphot - SA + UFX-DX instrument (Nikon) 
to yield 100x, 200x, 400x magnifications. 
Assay for antiproliferative effect. The effects of increasing concentrations of the drugs on cell growth 
were examined in 96-well flat-bottomed microtitre plates. The stock compounds were dissolved in 
DMSO to yield a starting concentration of 50 µg/ml in a final volume of 150 µl. Two-fold dilutions with 
2% DMSO and 50 µg/ml compounds were made; the final concentration of DMSO was 0.0156% and the 
final concentration of the compounds were 1.5625 µg/ml. DMSO was used as a control. A total of 6×103 
cells in 50 µl of media were then added to each well, with the exception of the media control wells. The 
culture plates were further incubated at 37°C for 72 h, at the end of which 15 µl of MTT solution (3-(4,5-
dimethyiltiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) thiazolyl blue solved in PBS to a final 
concentration of 5 mg/ml) were added to each well. After further incubation at 37°C for 4 h, 100 µl of 
sodium dodecyl sulphate (SDS) solution (10% + 1 N HCl) were added to each well and the plates were 
further incubated overnight in a 5% CO2 incubator at 37○C. Cell growth was determined by measuring the 
optical density (OD) at 550 nm (ref. 630 nm) with a Multiscan EX ELISA reader (Thermo Fisher 
Scientific). Inhibition of cell growth was determined as a percentage according to the formula: 
 5


 
 100100
controlmediumODcontrolcellOD
controlmediumODcellstreatedOD  
 
Assay for reversal of MDR in tumor cells by flow cytometry. The cells were adjusted to a density of 
2×106 cells/ml, resuspended in serum-free media and distributed in 0.5 ml aliquots (1×106 cells) into 1.5 
ml Eppendorf centrifuge tubes. The cells were incubated in the presence of compounds for 10 min at 
room temperature. Then, indicator ABCB1-substrate rhodamine 123 (R123) (Sigma-Aldrich) was added 
to each sample at a final concentration of 10 µg/ml and the cells were incubated for a further 20 min at 
37○C in water bath, washed twice and resuspended in 0.5 ml PBS for analysis. The fluorescence of the 
cell population was measured in FL1 at 540 nm (ref. 630 nm) wavelength with a FACS Star Plus flow 
cytometer (Beckton, Dickinson and Company). Verapamil hydrochloride (EGIS) was used as a positive 
control at a final concentration of 10 µg/ml. 
The results presented are obtained from a representative flow cytometric experiment in which 1×104 
individual cells of the population were evaluated for the amount of the retained R123. The percentage 
mean fluorescence intensity was calculated for the PAR/MDR and A2780/A2780cis cell lines, treated 
cells were compared to the untreated ones. Fluorescent activity ratio (FAR) was calculated via the 
following equation, on the basis of the measured fluorescence values: 
controlparentaltreatedparental
controlMDRtreatedMDRFAR   
 
Assay for combination of chemotherapy. A checkerboard microplate method was applied to study the 
effects of interactions between the resistance modifiers and the anticancer agent doxorubicin (Ebewe) on 
MDR cells or cisplatin (EGIS) on A2780cis cells as an in vitro model of combination chemotherapy. The 
combinations were carried out in a final volume of 200 µl. Doxorubicin or cisplatin (A) was measured 
into the 96-well microtitre plate in a horizontal direction in two-step dilutions, the highest final 
concentrations were 8 µg/ml or 20 µg/ml, respectively. The resistance modifiers (B) were diluted 
vertically in two-step dilutions. The cell suspension in tissue culture media (supplemented McCoy'5A 
without colchicine or RPMI 1640) was distributed into each well in 50 µl containing 1×104 MDR cells or 
2×104 A2780cis cells. The plates were incubated in a CO2 incubator at 37○C for 48 h. The cell growth 
rate was determined after MTT staining and the intensity of the blue color was measured with a Multiscan 
EX ELISA reader. Drug interactions were evaluated according to the following system: 
 FICA = IC50A combination / IC50A alone 
 FICB = IC50B combination / IC50B alone 
where IC = inhibitory concentration and FIC = fractional inhibitory concentration. FIX = FICA+FICB, 
where FIX = fractional inhibitory index. FIX < 0.5 indicates synergism, 0.5 < FIX < 4 indicates no 
interaction (addition), and FIX > 4 indicates antagonism between the anticancer drug and the potential 
MDR modifier. 
Assay for apoptosis induction. Apoptosis induction in the presence of various compounds on MDR and 
A2780cis cells was determined. The MDR cells were adjusted to a density of 1×106 cells/ml and were 
distributed in 0.5 ml aliquots into microcentrifuge tubes. Then, drugs were added to the samples to 
determine their effect in apoptosis induction. 12H-benzo(a)phenothiazine (M627) was used as a positive 
control of apoptosis at a final concentration of 50 µg/ml. The MDR cells were incubated at 37○C for 45 
min in water bath, then washed twice with PBS and resuspended in 0.5 ml McCoy’s 5A media. The 24h 
incubation was carried out in a 5% CO2 incubator at 37○C. 
The suspension of A2780cis ovarian cancer adherent cells were diluted to 1.5×106 cells/ml and 
distributed into 24-well culture plates for 4 h in 750 µl aliquots to let the cells attach. Then, the 
compounds were added, M627 was used as a control for apoptosis at a final concentration of 50 µg/ml, 
and paraformaldehide was used as a control for necrosis. Apoptosis induction on the A2780cis cells was 
conducted over a period of up to 3 h in the presence and absence of the compounds; the samples were 
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then washed with PBS and resuspended in RPMI media. The 24 h incubation was carried out in a 5% CO2 
incubator at 37○C. 
MDR cells were transferred into 1.5 ml Eppendorf-tubes. The apoptosis assay was carried out 
according to the Rapid Annexin V Binding Protocol of Annexin V-FITC Apoptosis Detection Kit 
(Calbiochem, Merck). Briefly, after transferring the MDR cells into Eppendorf-tubes, 10 µl of Media 
Binding Buffer was added to each sample, then 1.2 µl Annexin V (AV)-FITC (fluorescein isothiocyanate) 
was measured to the samples. In case of A2780cis cells, 15 µl of Media Binding Buffer and 1.2 µl AV-
FTIC was added into the wells of the 24-well plate. The samples (both MDR and A7820cis) were 
incubated at room temperature for 15 min in the dark. Then, after washing the cells in PBS, the samples 
were centrifuged at 2000 g for 3 min at room temperature, and the media was removed. The cells were 
resuspended in 0.5 ml ice-cold 1x Binding Buffer, then, stored on ice. 10 µl propidium iodide (PI) was 
added to the samples at a final concentration of 1.5 µg/ml, and the samples were analyzed immediately by 
measuring the fluorescence activity. AV was measured in FL1 at 540 nm, and PI was measured in FL3 at 
680 nm wavelength. 2×104 cells of the gated population were measured in each sample by a FACS Star 
Plus flow cytometer (Beckton, Dickinson and Company). 
DNA extraction from human blood for PCR. Ethical Permission was approved by the Human 
Investigation Review Board at the Albert Szent-Györgyi Clinical Centre. All patients gave their inform 
consents to the examination. In our experiments most of the cancer patients (69 of 88) selected for SNP 
analysis had been treated by chemotherapy previously, the therapies were carried out according to the 
variable protocols of certain cancer types. The patients were divided into two groups: gynecological 
cancer group (ovarian and cervical cancer, n=31), and a mixed cancer group (n=57). A group of healthy 
volunteers (n=99) was applied as control. 
Venous blood was taken into 3 ml tubes anticoagulated with EDTA at the Regional Blood 
Transfusion Centre (University of Szeged). The DNA extraction was carried out by a modified salting out 
protocol. Briefly, 400 µl blood was resuspended in a 1.5 ml Eppendorf centrifugation tube with 600 µl 
distilled water and 250 µl of nuclei lysis buffer (50 µM Tris-HCl pH 7.5, 22.7% Triton X-100, 20 µM 
MgCl2 and 140 µM saccharose). After washed twice with 600 µl distilled water (10.000 rpm, 3 min), the 
cell lysates were digested overnight at 37°C with 40 µl of 10% SDS, 80 µl 5x proteinase-K buffer (0.3 M 
NaCl and 0.1 M EDTA pH 8.0) and 20 µl of a protease K (20 mg/ml, Fermentas) solution. After 
digestion, 150 µl of 5M Na-acetate was added to each tube and shaken vigorously for 15 sec, and 
centrifuged at 13.000 rpm for 3 min. The precipitated protein pellet was left at the bottom of the tube and 
the supernatant containing the DNA was transferred to another 1.5 ml Eppendorf centrifugation tube. 600 
µl of pre-cooled isopropanol (-20○C) was added to each tube and the tubes were inverted several times 
until the DNA precipitation. After centrifugation at 13.000 g for 3 min, the supernatant was discarded and 
800 µl of pre-cooled ethanol (-20○C, 70%) was added to the pellet. After the final centrifugation step at 
13.000 g for 3 min, the supernatant was discarded again, and the DNA was dried at room temperature. 
For the PCR experiments, DNA was dissolved in 25 µl PCR-clean DNAse and RNAse free distilled-
water (Fermentas). The concentration of the DNA was measured by NanoDropTM 1000 (Thermo Fisher 
Scientific). 
Evaluation of SNPs by PCR-RFLP. These experiments were carried out at the Institute of Integrative 
and Comparative Biology (University of Leeds, United Kingdom). Polymerase chain reaction – 
restriction fragment length polymorphism (PCR-RFLP) was applied to identify ABCB1 (rs2032582, 
rs1045642), P53 (rs1042522), BCL2 (rs2279115) and BAX (rs4645878) SNPs. Each PCR was performed 
in a 20 µl reaction mixture containing 10-100 ng of genomic DNA templates, 0.5 pM of each primer 
(Sigma-Aldrich), 2 mM of each deoxynucleoside triphosphate (Promega), 10x PCR buffer, 2.5 mM 
MgCl2, and 0.5 U Taq polymerase (BIOTAQTM Red DNA Polymerase, Bioline). The PCR profile 
consisted of an initial denaturation step of 96○C for 5 min, 35 cycles of 96○C for 45 s, 56○C for 40 s and 
72○C for 30 s and a final extension step of 72○C for 10 min in a 2720 Thermal Cycler (Applied 
Biosystems). 
ABCB1, BAX, BCL2 and P53 polymorphisms were examined by the digestion of 5 µl of PCR 
product by 2 U of restriction enzyme (New England Biolabs) in a final volume of 10 µl at 37○C overnight 
(BanI, DpnII, MspI, BccI) or at 60○C for 4 h (BstuI), then evaluated by gel electrophoresis on 2% agarose 
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gel (Sigma-Aldrich). The sequences of the primers and fragment length of selected SNPs are presented in 
Table I. 
 
Table I. Cancer-related single nucleotide polymorphisms selected for SNP studies examined by PCR-RFLP. 
Gene SNP primer sequence RE size (bp) 
MDR-9 (f) 5`-TgCAggCTATAggTTCCAgg-3` rs2032582 
MDR-10 (r) 5`-TTTAgTTTgACTCACCTTCCCg-3` 
BanI 198, 26; 224  
MDR-11 (f) 5`-TgTTTTCAgCTgCTTGATgg-3` 
ABCB1 
rs1045642 MDR-12 (r) 5`-AAggCATgTATgTTggCCTC-3` DpnII  158, 39; 197 
BAX1 (f) 5`-CATTAgAgCTgCgATTggACCg-3` BAX rs4645878 BAX2 (r) 5`-gCTCCCTCgggAggTTTggT-3` MspI 20, 89; 109 
BCL1 (f) 5`-CTgCCTTCATTTATCCAgCA-3` BCL2 rs2279115 BCL2 (r) 5`-ggCggCAgATgAATTACAA-3` BccI 189, 111; 300 
P53A (f) 5`-ATCTACAgTCCCCCTTgCCg-3` P53 rs1042522 P53B (r) 5`-gCAACTgACCgTgCAAgTCA-3` BstUI 169, 127; 296 
Rs: reference sequence number. (f) and (r) represents forward and reverse primers. RE: restriction endonuclease. 
Bp: base pair. Product size after digestion: wild type alleles digested, variant alleles undigested in italics 
underlined. Bases: A – adenine, C – cytosine, g – guanine, T – thymine. 
 
Statistical analysis. Statistical analyses for comparison of genotype frequencies between groups was 
performed by using the χ2 (chi-square) test, and Fisher's exact test when the values in any of the cells of a 
contingency table was below 10 with only one degree of freedom. The relationship between genotypes 
and cancer is presented as the odds ratio (OR), with a 95% confidence interval (CI). Genotype 
distributions and deviation from Hardy-Weinberg equilibrium (HWE) were tested separately for both 
cases and controls with SPSS (SPSS for Windows 16.0) and HWE calculator. All statistical tests were 
two-sided, a P value of 0.05 was considered significant. Power and sample size (PS) was determined by 
the PS program version 3.0. 
 
RESULTS AND DISCUSSION 
Immunocytochemistry 
High level of ABCB1 expression was detected in the membrane of MDR cells; whereas in the A2780cis 
cells and in the control cells ABCB1 expression could not be shown. Specific staining of the cytoplasm 
was detected when using MRP1 specific MAB on both MDR and A2780cis cell lines. Estrogen and 
progesterone hormone receptors were undetectable in the examined cell lines; however, in the case of 
control breast cancer MCF7 cell line they were detectable.  
In our experiments it was revealed that this A2780cis cell line does not overexpress either of the 
two hormone receptors of estrogen and progesterone. Hence, we assume that the effects of our 
extensively examined steroid-type compounds can be basically different from that of hormone-dependent 
tumors. The mechanism of cisplatin resistance in the A2780cis cells is still not fully determined, 
therefore, further investigation is required. The resistance is supposedly due to a multifactorial 
mechanism including altered transporter expression patterns, mismatch repair and cell-cycle modification. 
 
Effect of selected compounds on cancer cells 
Various compounds have been investigated for their ability to reverse drug and multidrug resistance, 
including synthetic and natural plant-derived compounds. In our experiments substituted steroids (I) and 
their platinum and copper complexes, hydantoin derivatives (II), alkaloids of Veratrum and Peganum 
species (III, IV), and saponins and phenolic components of Tribulus terrestris and Smilax excelsa (V) 
were evaluated. 
Semisubstituted steroids and selected platinum and copper coordination complexes (I). A number of 
steroid-type molecules have been described previously to prevent drug and multidrug resistance in cancer. 
Furthermore, specifically modified compounds have also been investigated, such as metal coordination 
complexes of tricyclic compounds, since it has been assumed that metals induce some changes in binding 
features to ABCB1. A number of studies have demonstrated that copper transporters CTR1 and CTR2, 
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and the ATPase copper efflux transporter α and β (ATP7AB) are responsible for transport of cisplatin. 
Therefore, we tried to combine the advantages of platinum and copper-based coordination complexes and 
resistance modifier steroid-based compounds in a wish to overcome drug resistance.  
In our study, thirty-five estrone- and androstane-type compounds (1-35) and copper and platinum 
complexes of selected compounds (4, 5, 25) were examined in a cisplatin-resistant human ovarian cancer 
cell line (A2780cis) and in a human ABCB1-expressing mouse lymphoma cell line (MDR). Eighteen 
compounds were effective as proliferation inhibitors with IC50 under 50 µg/ml on A2780cis cell line, and 
fourteen were found to inhibit cell proliferation on MDR cell line. Only two compounds (9 and 34) were 
active on both cell lines. 
Then, the compounds were examined as potent resistance inhibitors. Seven of the substituted 
steroids were found to be effective in inhibition of resistance on both cell lines. On the basis of the 
activity of the steroid samples, certain tendencies seem to be present. Both androstane derivatives and 
estrone ethers can be found among the active and inactive groups of compounds, consequently, the 
activity does not depend on the structure of the skeleton. Thus, it is rather the nature and arrangement of 
the functional groups that determine the activity of the compound. Compounds containing a primary 
amino function with O-acetyl or N-acetyl groups were cytotoxic for both cell types. Very polar 
compounds containing two or more hydroxyl groups or secondary amino groups were ineffective in our 
examinations. But most of the samples, where these groups are arranged on the D-ring of the skeleton and 
the O or N atom of the functional group was at 1,3-position to D-ring were found to be active in both cell 
types. This structural arrangement may serve as a binding moiety on the polar protein-glycan surface of 
the cells and can result in an effect independent of the structure of the A ring. The distance between X and 
Y (300-400 pm) may allow a supramolecular connection on the peptide chain of the cell surface by polar-
polar interaction (Figure 1). Our in vitro experimental data indicate that some of the steroid-type synthetic 
molecules can be regarded as promising structures for rational drug design as resistance inhibitors with a 
novel mechanism of action. 
 
Figure 1. Structure of the most active five semisubstituted steroid 
compounds examined in the MDR reversal assay on both 
A2780cis and MDR cell lines. Their common feature is the O or 
N atom in 1,3-position to D-ring. The distance between X and Y 
(300-400 pm) may allow a supramolecular connection on the 
peptide chain of the cell surface by polar-polar interaction. 
 
Then, we evaluated the interaction between anticancer agents and steroid-derivatives. On A2780cis 
cell line, we did not find synergistic interaction between cisplatin and any of the steroid-type compounds. 
On MDR cell line, one compound (11) showed synergism with doxorubicin (FIX = 0.45) and another 
compound (25) was found to be weakly synergistic (FIX = 0.47).  
After the evaluation of these thirty-five steroids in both cell types, three compounds (4, 5, 25) were 
selected to determine their effect in platinum and copper complexes. Copper-steroid complexes seem to 
be better inhibitors of cell proliferation than platinum-steroid complexes on both cell lines according to 
the IC50 values. In A2780cis cells, none of the complexes were found to be better resistance inhibitors 
than pure steroids at a final concentration of 40 µg/ml. In MDR cells, both platinum and copper 
complexes were effective resistance inhibitors at 40 µg/ml concentration. In these experiments, all 
compounds were evaluated at ten-fold lower concentrations (4 µg/ml) as well, and the FAR values were 
found to be about four-fold lower. This means that these compounds act in a concentration-dependent 
manner, and at the higher concentration the membrane-embedded ABCB1 transporters might be 
oversaturated. 
In the apoptosis induction experiments none of the tested compounds induced apoptosis in 
A2780cis human ovarian cancer cells or in MDR mouse lymphoma cells. However, a non-significant 
increase of the percentage of apoptotic population was observed when evaluated in A2780cis cells, but 
the higher dose of compounds 25 and 25C only resulted in an increase of non-apoptotic dead cell 
population. Most likely these selected compounds at higher concentrations directly alter membrane 
structure rather than modify apoptotic pathways, thus, inducing necrosis and avoiding complete apoptosis 
in these two examined cell lines. 
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Hydantoin derivatives (II). Various aspects of the biochemical and pharmacological properties of 
hydantoin derivatives have been studied such as fungicidal, herbicidal and anti-inflammatory properties. 
Previously, the cytotoxic activity of spirohydantoin derivatives has been tested on ovarian and breast 
cancer cell lines. Furthermore, it has been shown that two spirohydantoin derivatives have inhibited cell 
growth and induced apoptosis in leukemia and colon cancer cells. Recent studies have shown that some 
diversely substituted diazaspirohydantoins has antiproliferative effect against MCF-7 breast carcinoma, 
HepG-2 hepatocellular carcinoma, HeLa cervix carcinoma and HT-29 colon carcinoma cell lines. The 
result of a recent study provided evidence to support the concept that introducing accessory metal centers 
is a viable strategy for augmentation of the cytotoxic activity of platinum drugs. Further data about the in 
vitro cytotoxicity of new platinum(II) complexes with hydantoin ligands have shown that 5-methyl-5-
phenylhydantoin, as well as the previously synthesized spirohydantoin compounds cyclopentane-
spirohydantoin and cyclohexane-spirohydantoin, exert concentration-dependent cytotoxic activity on a 
panel of tumor cell lines, although less pronounced than that of the reference drug cisplatin. 
In our experiments, thirty hydantoin derivatives were evaluated. First, the IC50 values were 
determined; they varied widely between 3 and 450 µg/ml. Non-toxic compounds with IC50 values under 
100 µg/ml were selected out of the 30 hydantoin derivatives for the MDR reversal experiments. 
Compound BS-1 was the most potent inhibitor of resistance (FAR = 77.68), this compound was active 
with FAR value of 46.71 at very low 0.4 µg/ml concentration. From the most effective compounds with 
high FAR values, nine compounds (AD-26, AD-29, RW-13, KF-2, BS-1, MN-3, RW-15b, JH-63 and SZ-
7) were chosen to determine the interaction with doxorubicin, out of these, most of the compounds except 
SZ-7 showed synergistic interaction on MDR cell line. 
All of the most active nine compounds contained aromatic substituents as well as some tertiary 
amine fragments. Furthermore, based on literature data, new platinum(II)-hydantoin complexes would be 
interesting to examine as possible anticancer agents. 
Steroidal alkaloids of Veratrum and Peganum species (III, IV). Alkaloids have extensive 
pharmacological actions including anticancer, anti-Alzheimer's disease, anti-diabetes, antimicrobial and 
anti-inflammatory activities. Vinca alkaloids are most famous for being anticancer agents, since they are 
well-known substrates of the ABCB1 transporter. Furthermore, it has been demonstrated that the 
cytotoxic effects of vinca alkaloids as well as those of podophyllotoxin against certain human tumor cells 
have been antagonized by cisplatin. Therefore, in our examinations, newly extracted alkaloids were 
considered to be promising as possible ABCB1-inhibitors. 
The present study was undertaken to access the inhibition of MDR of cancer cells by alkaloids (A1-
9) isolated from Veratrum lobelianum, V. nigrum and Peganum nigelastrum. Plants from genus Veratrum  
and genus Peganum were traditionally used as medicinal substances in Mongolia for a long time. The 
main chemical ingredients in V. lobelianum, V. nigrum and P. nigelastrum species are steroidal and 
indole-type alkaloids.  
In this experiment, some steroidal alkaloids moderately inhibited the cell proliferation of MDR 
cells. The IC50 values were found to be between 20.76 and 26.07 µg/ml for compounds A1-3, A5 and A6. 
The MDR reversal effects of the alkaloids were examined on MDR cells and the most active compounds 
were verabenzoamine (A2), veralosinine (A5) and veranigrine (A6) and with FAR values of 87.00, 93.26 
and 88.81 at final cc. of 40 µg/ml, respectively. 
The mechanism by which these steroidal alkaloids inhibit ABCB1 activity is currently unknown. 
However, structurally, these steroidal alkaloids are small lipophilic molecules with planar polycyclic 
skeleton and tertiary nitrogen atom and are likely to be able to enter cells by passive diffusion. Although, 
it is difficult to find structural features that are common to a large number of chemosensitisers, it has been 
suggested that resistance modifier agents are hydrophobic, contain two or more planar aromatic rings and 
tertiary nitrogen. The structure of steroidal alkaloids fits this profile. 
Saponins and phenolic components of Tribulus terrestris and Smilax excelsa (V). Saponins are 
generally found in the roots, flowers and seeds of  plants and have long been used against various diseases 
to enhance natural resistance. In a recent study it has been found that tubeimoside I, a triterpenoid saponin 
extracted from Bolbostemma paniculatum (Cucurbitaceae), sensitizes to cisplatin in cisplatin-resistant 
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A2780cis human ovarian cancer cells. Hence, we evaluated eleven saponins and structurally related 
compounds (S1-S11) isolated from T. terrestris and S. excelsa in order to find new resistance modifiers.  
All of the examined compounds were found to be moderate proliferation and MDR inhibitors on 
MDR cell line. Furthermore, in the combination experiment with doxorubicin it was found that one of 
these eleven saponins, methyloprototribestin (S2) can act in a synergistic manner. 
When evaluating the structure-activity relationship, it was found that the activity of these saponins 
appears to correlate the position of sulphur-containing substituents; this may refer to the role of charge 
transfer complex formation while binding of these compounds to ABCB1. Since it has already been 
demonstrated that saponins can sensitize A2780cis cancer cell to cisplatin, these new compounds isolated 
from T. terrestris and S. excelsa would be promising candidates as adjuvants in cisplatin-resistant cancer 
therapy. 
 
SNP analysis to determine their role in cancer 
Complex SNP studies may be a way of personal risk assessment and could serve as a possible treatment 
predictive marker for chemotherapy in several cancer types. Certain hereditary SNPs in cancer patients 
are assumed to increase the development of cancer, for instance, by inducing conformational changes in 
the encoded protein. Therefore, we evaluated some SNPs in cancer-related genes to determine cancer risk.  
In our experiments, most of the cancer patients (69 of 88) selected for SNP analysis had been 
treated with chemotherapy, the therapies were carried out according to the variable protocols of certain 
cancer types. The patients were divided into two groups: gynecological cancer group (ovarian and 
cervical cancer, n = 31), and a mixed cancer group (n = 57), and a group of healthy volunteers (n = 99) 
was applied as control group. 
The correlation of anticancer therapies and the success of treatment are not discussed in this thesis 
because the sample size is not big enough to draw the inference in statistical analysis. Since, we focused 
on hereditary SNPs that have been already included in the genome of healthy volunteers and patients 
before cancer developed, genomic DNA was extracted from blood, but not from the cancer tissue itself. 
No significant differences in ABCB1 and BCL2 genotype frequencies were found between cancer patients 
and the control group. However, it has already been verified previously that these examined SNPs are in 
correlation with ABCB1 levels and uptake of its substrates and disease outcome. Significant differences 
in BAX genotype frequencies with allele G (P < 0.001, OR = 3.561), or positive trend in P53 genotype 
frequencies with allele C (P = 0.05917, OR =1 .622) were found between the mixed cancer group and the 
control group. 
The data obtained in our study suggest that the allelic variants of BAX may be predictive marker of 
cancer. However, in this preliminary study only a limited number of samples were included. Further 
investigation is required to determine the correlation between ABCB1 allelic variants and their expression 
levels in chemotherapy-resistant cancer.  
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NEW RESULTS RELATED TO THE THESIS 
 
1. Immunocytochemistry 
We demonstrated that the cisplatin-resistant A2780cis cell line does not express any of the ABCB1 and 
MRP1 transporters, and any of the hormone receptors of estrogen and progesterone. 
 
2. Effects of compounds in A2780cis and MDR cancer cell lines 
2.1. Antiproliferative effect 
Several compounds were found to be good proliferation inhibitors in A2780cis and MDR cell lines. 
Copper-steroid coordination complexes seem to be better inhibitors of cells proliferation than platinum-
steroid coordination complexes in both A2780cis and MDR cell lines. 
Numerous compounds were found to significantly inhibit cell proliferation of MDR cells including 
semisubstituted steroids, hydantoin derivatives, steroidal alkaloids and saponins and phenolic 
components. 
2.2 Reversal of drug resistance  
Several substituted steroids were effective in the MDR reversal experiments in A780cis and MDR cell 
lines. Some steroids (2, 5, 6, 12, 22, 25, 27) were found to be effective proliferation inhibitors in both 
A2780cis and MDR cells. When comparing structure, it seems that the activity does not depend on the 
structure of the skeleton, but it is rather the nature and arrangement of the functional groups that 
determine the activity. 
Numerous hydantoin derivatives and natural compounds (steroidal alkaloids and phenolic 
components, and saponins) reversed resistance of MDR mouse lymphoma cells. 
2.3 Interaction of selected compounds and anticancer agents 
None of the complexes were found to be in synergistic interaction with the anticancer agent cisplatin in 
A2780cis cells. In MDR cells, one the steroid-type molecules with androst-5-ene structure (11) was found 
to have a synergistic effect in combination with doxorubicin; compound 25 showed some synergism as 
well. 
Eight hydantoin derivatives (AD-26, AD-29, RW-13, KF-2, BS-1, MN-3, RW-15b, JH-63) 
containing aromatic substituents and some tertiary amine fragments showed synergistic interaction with 
doxorubicin in MDR cells. 
The most active alkaloids in the combination experiments in MDR cells were veralosinine (A5) and 
veranigrine (A6). Both are hydrophobic compounds containing two or more planar aromatic rings and a 
tertiary nitrogen.  
Methylprototribestin (S2) was found to be the only saponin that had some synergistic interaction 
with doxorubicin in MDR cells. 
2.4 Apoptosis induction 
None of the steroid-type platinum and copper complexes was able to induce apoptosis either in A2780cis 
or in MDR cells. 
 
3. SNP analysis to determine their role in cancer  
The SNP nr. rs2279115 in BAX gene may be predictive of cancer development, allele G might increase 
the probability of developing cancer. In case of the other four SNPs of ABCB1, BCL2 and P53 genes, no 
significant differences were found between cancer patient and healthy volunteer groups. In case of 
ABCB1, strong linkage disequilibrium was measured between its two SNPs nr. rs2032582 and rs1045642. 
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